Ultragenyx Announces Top-Line Results From Phase 3 Study of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced positive topline results from its Phase 3 study of DTX401 gene therapy for Glycogen Storage Disease Type Ia. The study showed a significant reduction in daily cornstarch intake and maintained glucose control, achieving its primary endpoint.
May 30, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx announced positive Phase 3 results for its DTX401 gene therapy, showing significant reduction in cornstarch intake for GSDIa patients. This achievement of the primary endpoint is likely to boost investor confidence and positively impact the stock price in the short term.
The positive Phase 3 results for DTX401, demonstrating a significant reduction in cornstarch intake and maintenance of glucose control, are likely to boost investor confidence. Achieving the primary endpoint in a clinical trial is a critical milestone, which often leads to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100